Ligand decorated biodegradable nanomedicine in the treatment of cancer
Copyright © 2021. Published by Elsevier Ltd..
Cancer is one of the major global health problems, responsible for the second-highest number of deaths. The genetic and epigenetic changes in the oncogenes or tumor suppressor genes alter the regulatory pathways leading to its onset and progression. Conventional methods are used in appropriate combinations for the treatment. Surgery effectively treats localized tumors; however, it fails to treat metastatic tumors, leading to a spread in other organs, causing a high recurrence rate and death. Among the different strategies, the nanocarriers-based approach is highly sought for, but its nonspecific delivery can cause a profound side effect on healthy cells. Targeted nanomedicine has the advantage of targeting cancer cells specifically by interacting with the receptors overexpressed on their surface, overcoming its non-specificity to target healthy cells. Nanocarriers prepared from biodegradable and biocompatible materials are decorated with different ligands by encapsulating therapeutic or diagnostic agents or both to target cancer cells overexpressing the receptors. Scientists are now utilizing a theranostic approach to simultaneously evaluate nanocarrier bio-distribution and its effect on the treatment regime. Herein, we have summarized the recent 5-year efforts in the development of the ligands decorated biodegradable nanocarriers, as a targeted nanomedicine approach, which has been highly promising in the treatment of cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Pharmacological research - 167(2021) vom: 21. Mai, Seite 105544 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ahmad, Ejaj [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 19.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.phrs.2021.105544 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322794188 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322794188 | ||
| 003 | DE-627 | ||
| 005 | 20231225182806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.phrs.2021.105544 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1075.xml |
| 035 | |a (DE-627)NLM322794188 | ||
| 035 | |a (NLM)33722711 | ||
| 035 | |a (PII)S1043-6618(21)00128-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ahmad, Ejaj |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ligand decorated biodegradable nanomedicine in the treatment of cancer |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 19.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Ltd. | ||
| 520 | |a Cancer is one of the major global health problems, responsible for the second-highest number of deaths. The genetic and epigenetic changes in the oncogenes or tumor suppressor genes alter the regulatory pathways leading to its onset and progression. Conventional methods are used in appropriate combinations for the treatment. Surgery effectively treats localized tumors; however, it fails to treat metastatic tumors, leading to a spread in other organs, causing a high recurrence rate and death. Among the different strategies, the nanocarriers-based approach is highly sought for, but its nonspecific delivery can cause a profound side effect on healthy cells. Targeted nanomedicine has the advantage of targeting cancer cells specifically by interacting with the receptors overexpressed on their surface, overcoming its non-specificity to target healthy cells. Nanocarriers prepared from biodegradable and biocompatible materials are decorated with different ligands by encapsulating therapeutic or diagnostic agents or both to target cancer cells overexpressing the receptors. Scientists are now utilizing a theranostic approach to simultaneously evaluate nanocarrier bio-distribution and its effect on the treatment regime. Herein, we have summarized the recent 5-year efforts in the development of the ligands decorated biodegradable nanocarriers, as a targeted nanomedicine approach, which has been highly promising in the treatment of cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a 5-Fluorouracil (PubMed CID: 3385) | |
| 650 | 4 | |a Biodegradable nanocarriers | |
| 650 | 4 | |a CD44 | |
| 650 | 4 | |a Cisplatin (PubMed CID: 5702198)) | |
| 650 | 4 | |a Coumarin-6 (PubMed CID: 100334) | |
| 650 | 4 | |a Curcumin (PubMed CID: 969516) | |
| 650 | 4 | |a Docetaxel (PubMed CID:148124) | |
| 650 | 4 | |a Doxorubicin (PubMed CID: 31703) | |
| 650 | 4 | |a Gemcitabine (PubMed CID: 60750) | |
| 650 | 4 | |a Hyaluronic Acid | |
| 650 | 4 | |a Paclitaxel (PubMed CID: 36314) | |
| 650 | 4 | |a Phospholipids | |
| 650 | 4 | |a Quercetin (PubMed CID: 5280343) | |
| 650 | 4 | |a Transferrin | |
| 650 | 4 | |a Triptolide (PubMed CID: 107985) | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Ligands |2 NLM | |
| 700 | 1 | |a Ali, Asgar |e verfasserin |4 aut | |
| 700 | 1 | |a Fatima, Munazza Tamkeen |e verfasserin |4 aut | |
| 700 | 1 | |a Nimisha |e verfasserin |4 aut | |
| 700 | 1 | |a Apurva |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Arun |e verfasserin |4 aut | |
| 700 | 1 | |a Sumi, Mamta P |e verfasserin |4 aut | |
| 700 | 1 | |a Sattar, Real Sumayya Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Mahajan, Bhawna |e verfasserin |4 aut | |
| 700 | 1 | |a Saluja, Sundeep Singh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacological research |d 1992 |g 167(2021) vom: 21. Mai, Seite 105544 |w (DE-627)NLM012597384 |x 1096-1186 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2021 |g day:21 |g month:05 |g pages:105544 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.phrs.2021.105544 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2021 |b 21 |c 05 |h 105544 | ||